Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia

This study has been completed.
Sponsor:
Information provided by:
Innovative Medical
ClinicalTrials.gov Identifier:
NCT00383396
First received: September 29, 2006
Last updated: February 12, 2007
Last verified: February 2007
  Purpose

To Determine if topical cyclosporine 0.05% BID prevents recurrent inflammation and improves comfort in eyes with pterygia.


Condition Intervention Phase
Pterygia
Drug: Topical Cyclosporine
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label

Resource links provided by NLM:


Further study details as provided by Innovative Medical:

  Eligibility

Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • pts with symptomatic pterygia unresponsive to palliative treatment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00383396

Locations
United States, Florida
Dr. Schechter
Boynton Beach, Florida, United States, 33426
Sponsors and Collaborators
Innovative Medical
Investigators
Principal Investigator: Barry Schechter, MD Florida Eye Microsurgical Institute
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00383396     History of Changes
Other Study ID Numbers: 1963
Study First Received: September 29, 2006
Last Updated: February 12, 2007
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Pterygium
Conjunctival Diseases
Eye Diseases
Cyclosporine
Cyclosporins
Anti-Infective Agents
Antifungal Agents
Antirheumatic Agents
Dermatologic Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 29, 2014